SkinBioTherapeutics plc
(the "Company")
Extension of research contract with University of Manchester
SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that, as envisaged in the Company's Admission Document dated 29 March 2017, it has agreed an eight month extension to its research contract with the University of Manchester to June 2018. This contract extension includes provision for the appointment of a second technician to the Company. This will increase the Company's ability to develop its SkinBiotix® platform.
Furthermore, the Company announces that it has recently demonstrated activity of SkinBiotix® at a range of doses in human skin models, and also completed the design of two human safety trials. If successful, these trials will allow the technology to be labelled 'dermatologically tested' for its cosmetic application.
Dr. Catherine O'Neill, CEO of SkinBioTherapeutics, said:
"We are making progress in our research, and the extension and expansion of our contract with the University of Manchester will allow meaningful progression across the Company. We are pleased with the progress of SkinBiotix, and are confident that it remains on track.
"As a team, we have nurtured relationships with industry stakeholders for many years. Since our IPO, we have continued to ensure potential commercial partners are aware of the capabilities of the SkinBiotix platform."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
SkinBioTherapeutics plc Dr. Catherine O'Neill, CEO Douglas Quinn, CFO |
Tel: +44 (0) 161 468 2760 |
Cairn Financial Advisers LLP Tony Rawlinson / Emma Earl / Richard Nash |
Tel: +44 (0) 20 7213 0880 |
Turner Pope Investments Ben Turner / James Pope |
Tel: +44 (0) 20 3621 4120 |
|
|
Instinctif Partners Melanie Toyne-Sewell / Alex Shaw |
Tel: +44 (0) 20 7457 2020 [email protected] |
|
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.
